Boston Scientific Reports the Acquisition of Silk Road Medical
Shots:
- Boston Scientific has signed a definitive agreement to acquire Silk Road Medical for $27.50 per share, making it an aggregate of ~$1.16B. The transaction will conclude in H2’24, contingent upon customary closing conditions
- The acquisition adds Silk Road Medical’s transcarotid artery revascularization (TCAR) technology, intended to prevent stroke & treat carotid artery disease, to the company’s vascular portfolio
- The TCAR procedure reverses the blood flow by accessing the carotid artery via a small neck incision to prevent plaque from dislodging. A stent is then positioned to stabilize plaque, preventing future strokes
Ref: Boston Scientific | Image: Boston Scientific
Related News:- Boston Scientific Corporation Highlights 6 Months Data of MODULAR ATP Study & 5 Years Data of APPRAISE ATP Study at Heart Rhythm 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
